Mubadala enhances life sciences portfolio

abu dhabi — Mubadala Investment Company, in cooperation with a consortium of investors, has participated in the completion of an investment deal in favour of Global Healthcare Opportunities (GHO) Capital Partners, the European specialist investor in healthcare.

The aim of the move is to strengthening its investments in Envision Pharma Group, a leading technology-enabled scientific communications company.

Global Healthcare Opportunities, together with the existing Envision management team and employees, have increased their investment in Envision Pharma Group.

The transaction sees GHO lead a consortium of its investors headed by Mubadala Investment Company, and including HarbourVest Partners and Northwestern Mutual to drive a new phase of growth, while Ardian exits its investment following a successful four-year partnership with Envision and GHO.

Founded in 2001, Envision helps biopharmaceutical and medical device companies com

mercialise new compounds through medical strategy, strategic publications planning, and medical communications delivery.

“Having worked alongside GHO for four years, we are delighted they have chosen to extend and deepen the partnership in a new investment cycle. We see a clear commitment to expanding our reach across the healthcare services spectrum, most notably in medical affairs, with the ultimate goal of enhancing physicians’ abilities to improve patient outcomes,” Envision CEO David Thompson said.

Over the last 19 years, Envision has enjoyed outstanding year-on-year organic growth. Consequently, its global reach now extends to Australia, Japan, Serbia and Hungary, with the company employing over 800 people across 14 offices.